Welcome to MITIGATE!
MITIGATE stands for Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours
Gastrointestinal stromal tumour (GIST) is a rare disease and frequently affects young patients and often results in a short life expectancy of less than 3 years. Currently there is only one class of effective medications, for systemic GIST therapy and often the tumours develop drug resistance after a few years. The MITIGATE consortium representing three European universities, three research organisations and four SMEs will pursue the ultimate goal to develop new protocols and guidelines to effectively diagnose and treat patients with metastatic GIST resistant to current treatment.
MITIGATE is co-funded by the European Community`s Seventh Framework Programme (FP7/2007-20013) under grant agreement no 602306 and will run from October 2013 – 2017.
Prof. Stefan Schönberg (Scientific Coordinator) & Dr. Pamela Zolda (Project Manager)